Trial Profile
Cardiovascular, Anthropometric, and Skeletal Effects of Antiretroviral Therapy (ART) Initiation With Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) Plus Atazanavir/Ritonavir (ATV/r), Darunavir/Ritonavir (DRV/r), or Raltegravir (RAL): Metabolic Substudy of A5257
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Atazanavir (Primary) ; Darunavir (Primary) ; Emtricitabine/tenofovir disoproxil fumarate (Primary) ; Raltegravir (Primary) ; Ritonavir (Primary)
- Indications HIV-1 infections
- Focus Pharmacodynamics
- 28 Jul 2021 Results of an exploratory retrospective analysis assessing whether skeletal muscle density and area are associated with markers of inflammation and immune activation in patients who were virologically suppressed at week 96 published in the JAIDS
- 11 Mar 2020 Results (n=214) presented at the 27th Conference on Retroviruses and Opportunistic Infections
- 23 Aug 2018 Results published in the Clinical Infectious Diseases